Humana Inc. (NYSE:HUM) had its target price decreased by Credit Suisse Group from $256.00 to $246.00 in a report issued on Friday morning. Credit Suisse Group currently has a neutral rating on the insurance provider’s stock.

Other equities research analysts have also issued research reports about the company. BidaskClub lowered Humana from a buy rating to a hold rating in a report on Wednesday, July 19th. Zacks Investment Research lowered Humana from a hold rating to a sell rating in a report on Thursday, July 27th. Piper Jaffray Companies reaffirmed a buy rating and issued a $246.00 price objective on shares of Humana in a report on Friday, July 14th. Jefferies Group LLC reaffirmed a hold rating and issued a $257.00 price objective on shares of Humana in a report on Friday, August 4th. Finally, Morgan Stanley lowered their price objective on Humana from $276.00 to $270.00 and set an overweight rating on the stock in a report on Thursday. Thirteen research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $252.81.

Humana (HUM) traded down $3.07 during midday trading on Friday, hitting $244.39. The company had a trading volume of 1,265,400 shares, compared to its average volume of 1,376,685. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.61 and a current ratio of 1.61. Humana has a 52-week low of $186.25 and a 52-week high of $264.56. The stock has a market capitalization of $34,913.58, a price-to-earnings ratio of 20.85, a P/E/G ratio of 1.68 and a beta of 0.91.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. During the same quarter in the previous year, the company earned $3.18 EPS. The firm’s revenue for the quarter was down 3.0% compared to the same quarter last year. equities analysts forecast that Humana will post 11.64 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Credit Suisse Group Trims Humana Inc. (HUM) Target Price to $246.00” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/credit-suisse-group-trims-humana-inc-hum-target-price-to-246-00/1699999.html.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, December 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.65%. Humana’s dividend payout ratio is currently 12.59%.

In other Humana news, insider William Kevin Fleming sold 3,071 shares of the business’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $250.98, for a total value of $770,759.58. Following the completion of the transaction, the insider now directly owns 7,681 shares in the company, valued at approximately $1,927,777.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $259.00, for a total value of $2,534,574.00. Following the completion of the transaction, the insider now owns 18,042 shares of the company’s stock, valued at $4,672,878. The disclosure for this sale can be found here. Insiders sold a total of 20,660 shares of company stock valued at $5,319,600 over the last quarter. 0.80% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Reliance Trust Co. of Delaware raised its holdings in Humana by 0.7% in the 2nd quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock valued at $270,000 after acquiring an additional 8 shares during the last quarter. Creative Planning raised its holdings in Humana by 0.3% in the 2nd quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock valued at $1,173,000 after acquiring an additional 15 shares during the last quarter. WFG Advisors LP raised its holdings in Humana by 4.5% in the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after acquiring an additional 20 shares during the last quarter. Cadence Capital Management LLC raised its holdings in Humana by 0.4% in the 2nd quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock valued at $1,367,000 after acquiring an additional 22 shares during the last quarter. Finally, Sit Investment Associates Inc. raised its holdings in Humana by 0.3% in the 2nd quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock valued at $2,892,000 after acquiring an additional 40 shares during the last quarter. Institutional investors own 96.15% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.